PRLD - Prelude Therapeutics Incorporated Stock Price, Fair Value and News

$1.30+0.41 (+46.07%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

PRLD Price Action

Last 7 days

62.5%

Last 30 days

35.4%

Last 90 days

-49.0%

Trailing 12 Months

-68.0%

PRLD RSI Chart

PRLD Valuation

Market Cap

71.5M

Price/Earnings (Trailing)

-0.54

Price/Free Cashflow

-0.67

PRLD Price/Earnings (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

PRLD Fundamentals

PRLD Earnings

Earnings (TTM)

-131.5M

Earnings Growth (Yr)

-5.43%

Earnings Growth (Qtr)

7.11%

PRLD Profitability

Return on Equity

-84.07%

Return on Assets

-66.69%

Free Cashflow Yield

-150.34%

PRLD Investor Care

Shares Dilution (1Y)

0.38%

Diluted EPS (TTM)

-1.77

PRLD Alerts

2 major insider buys recently.

Revenue & Growth

About Prelude Therapeutics Incorporated

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma. The company is also developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 2 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.

CEO	Dr. Krishna Vaddi D.V.M., Ph.D.
WEBSITE	https://preludetx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	122

Prelude Therapeutics Incorporated Frequently Asked Questions

What is the ticker symbol for Prelude Therapeutics Incorporated? What does PRLD stand for in stocks?

PRLD is the stock ticker symbol of Prelude Therapeutics Incorporated. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Prelude Therapeutics Incorporated (PRLD)?

As of Fri Dec 20 2024, market cap of Prelude Therapeutics Incorporated is 71.55 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PRLD stock?

You can check PRLD's fair value in chart for subscribers.

Is Prelude Therapeutics Incorporated a good stock to buy?

The fair value guage provides a quick view whether PRLD is over valued or under valued. Whether Prelude Therapeutics Incorporated is cheap or expensive depends on the assumptions which impact Prelude Therapeutics Incorporated's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PRLD.